Zenas BioPharma
To transform the lives of patients living with autoimmune diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | $225m | IPO |
| Total Funding | 000k | ||
| USD | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (90 %) | 160 % | 64 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (34 %) | (3275 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (74 %) | (3140 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 120 % | 2783 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Zenas BioPharma is a global biopharmaceutical company focused on developing and commercializing immunology-based therapies for patients with autoimmune diseases. The company operates in the biopharmaceutical market, targeting patients in need of innovative treatments for autoimmune conditions. Zenas BioPharma's business model centers on advancing a deep pipeline of therapeutics through successful business development strategies and partnerships. The company generates revenue by developing and commercializing these therapies, aiming to bring transformative solutions to patients worldwide. Zenas BioPharma serves a diverse client base, including healthcare providers, patients, and research institutions, and leverages its experienced leadership team and network of business partners to drive operational excellence.
Keywords: autoimmune, therapeutics, biopharmaceutical, immunology, innovative, pipeline, commercialization, partnerships, leadership, global.